The adjunctive use of topical corticosteroids and/or corneal cross-linking (CXL) with riboflavin in the treatment of bacterial keratitis have long been debated.1-4 The recent Steroids and Cross-Linking Ulcer Treatment Trial II (SCUT II) trial primary outcome revealed no benefit or harm of adjunctive corticosteroids at 6 months in terms of best spectacle-corrected visual acuity (BSCVA) and infiltrate and/or scar size; CXL offered no benefit in BSCVA and resulted in increased scar size at 6...
Rahul Ramesh
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Rahul
Contact Rahul, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack